Survodutide

What Is Tesamorelin and How Does It Work? Tesamorelin is a synthetic 44-amino acid analogue of growth hormone-releasing hormone (GHRH), with a longer duration of action in the body. It stimulates the pituitary to release growth hormone, increasing insulin-like growth factor-1 (IGF-1) production. Elevated IGF-1 supports fat breakdown, glucose metabolism, and cell survival [1]. Tesamorelin Research Originally approved to treat HIV-associated lipodystrophy, tesamorelin has been shown to significantly reduce visceral adipose tissue [1]. Emerging research is now exploring its broader therapeutic potential, including liver health, cardiometabolic risk, and neurological health. Reducing Visceral Fat Clinical trials consistently show that tesamorelin reduces visceral adipose tissue (VAT) in people with HIV and central adiposity. Across studies, about 70% of participants were considered “responders,” achieving at least an 8% VAT reduction within 26 weeks [2], [3]. Importantly, the benefits extended beyond fat volume: tesamorelin also improved fat quality, with significant increases in VAT density compared to placebo [2]. This shift suggests a move toward smaller, healthier adipocytes and a more favorable metabolic profile [2]. These effects were observed regardless of baseline fat levels. In a large phase III trial of 806 participants, most experienced meaningful VAT reductions [3]. A separate trial of 412 subjects found that tesamorelin produced a selective 1-kg reduction in visceral fat over six months, with little effect on subcutaneous or limb fat [4]. Participants also reported less distress about abdominal size [4]. Overall, tesamorelin demonstrates clinically significant, treatment-dependent benefits for both VAT quantity and quality, although gains tend to diminish after discontinuation [5]. Liver Health Benefits Tesamorelin has shown consistent liver-related benefits, particularly in people with HIV. In one study, higher baseline VAT was associated with elevated liver enzymes (AST and ALT) [3]. Participants who responded to tesamorelin with significant VAT reduction also demonstrated improvements in AST and ALT. These hepatic benefits persisted even after treatment discontinuation despite partial VAT regain [3]. Randomized controlled trials corroborate this. In HIV-associated fatty liver disease, tesamorelin reduced liver fat and prevented fibrosis progression over 12 months [6]. Liver biopsies revealed upregulation of oxidative phosphorylation pathways, enhanced mitochondrial function, and downregulation of genes tied to inflammation, tissue repair, and cell proliferation—all processes linked to fibrosis and liver injury [6]. Importantly, tesamorelin also shifted gene expression toward patterns associated with a more favorable liver cancer prognosis [6]. A 12-month double-blind trial confirmed these findings, showing a 4.1% absolute and 37% relative reduction in hepatic fat fraction. By the study's end, 35% of the tesamorelin-treated participants achieved liver fat <5%, compared with only 4% of placebo participants [7]. Cardiometabolic Health and Muscle Mass In people with HIV and antiretroviral therapy-associated lipodystrophy, tesamorelin also improved lipid profiles, improving triglycerides and cholesterol ratios without impairing glucose tolerance [4]. Similar effects were seen in abdominally obese adults with reduced growth hormone (GH) secretion, where 12 months of therapy reduced VAT by 35 cm² while preserving subcutaneous fat [8]. This was accompanied by reductions in triglycerides, C-reactive protein, and carotid intima-media thickness, indicating improvements in systemic inflammation and cardiovascular risk. IGF-1 levels rose significantly, confirming GH pathway activation, while glucose measures remained stable [8]. In type 2 diabetes, tesamorelin modestly improved lipid levels without impairing insulin sensitivity [9]. Additional findings suggest enhanced mitochondrial and muscle function, with improved phosphocreatine recovery after exercise [10]. Pooled phase III trial analyses confirm durable VAT reductions, lipid improvements, and better body image ratings [11]. Furthermore, reductions in excess visceral fat were linked to lower predicted 10-year atherosclerotic cardiovascular disease (ASCVD) risk, largely mediated by cholesterol improvements [12]. Neurological Health The natural age-related decline of GHRH, GH, and IGF-1 may contribute to age-related cognitive changes. This explains why tesamorelin also improves brain health. Aside from improving neurological health through metabolic changes and immunomodulation, tesamorelin also positively affects neurotransmitter balance. In antiretroviral therapy-treated HIV patients, abdominal obesity was linked to neurocognitive impairment. In a six-month trial, tesamorelin-treated participants achieved a significant waist circumference reduction and improvement in cognition [13]. In older adults and those with mild cognitive impairment (MCI), 20 weeks of tesamorelin treatment improved cognition and neurochemistry. The cognitive improvements corresponded with higher brain GABA (gamma-aminobutyric acid), increased N-acetyl-aspartyl-glutamate in the frontal cortex, and reduced myo-inositol in the posterior cingulate cortex [14]. In another trial enrolling 152 adults, 20 weeks of tesamorelin improved executive function and verbal memory, and was associated with a 117% IGF-1 increase, reduced body fat, and mild adverse events [15]. Other studies suggest GHRH and growth hormone-based therapies may promote peripheral nerve regeneration by supporting axonal growth, limiting muscle atrophy, and enhancing repair processes [16].

Snapshot Tesamorelin, CJC-1295 No DAC, and ipamorelin are a combination of investigational peptides that engage complementary growth hormone–releasing hormone (GHRH) and ghrelin receptor (GHS) pathways to modulate endogenous growth hormone pulsatility. Mechanistic studies support GHRH–GHS cross-talk, though direct clinical evaluation of this three-peptide combination remains limited. What Is Tesamorelin? Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) consisting of 44 amino acids, designed to stimulate endogenous growth hormone (GH) secretion from the anterior pituitary. By activating the GHRH receptor, tesamorelin promotes pulsatile GH release and downstream increases in insulin-like growth factor-1 (IGF-1), while preserving physiologic feedback regulation. Tesamorelin has been studied in metabolic research contexts for its ability to metabolize fat while maintaining muscle mass, particularly in HIV patients [1]. What Is CJC-1295 Without DAC? CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone that retains the core bioactive sequence of native GHRH but lacks the drug affinity complex (DAC) modification. As a result, it has a shorter functional half-life and more closely mimics physiologic, pulsatile GH signaling rather than sustained elevation. By binding to the GHRH receptor on pituitary somatotrophs, CJC-1295 without DAC stimulates endogenous growth hormone release and downstream IGF-1 production in a natural and feedback-regulated manner [2]. In research settings, it is often used as a tool to engage the GHRH axis without prolonged GH exposure. What Is Ipamorelin? Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively activates the ghrelin (GHS-R1a) receptor in the hypothalamus and pituitary. Through this pathway, ipamorelin promotes pulsatile growth hormone release without significantly stimulating other pituitary hormones such as cortisol or prolactin [3]. In research models, ipamorelin is a commonly studied complement to GHRH analogs when examining coordinated regulation of the somatotropic axis. Synergy This three-peptide combination is best understood as a multi-node strategy to engage the somatotropic axis. Two components, tesamorelin and CJC-1295 No DAC, are GHRH-pathway agonists, while ipamorelin activates the ghrelin/GHS-R1a pathway, a distinct control system that can amplify GH release through complementary signaling. Tesamorelin and CJC-1295 Both tesamorelin and CJC-1295 without DAC stimulate the GHRH receptor on pituitary somatotrophs, via adenylyl cyclase activation and increased cAMP, supporting physiologic GH pulse generation when pituitary function is intact. Ipamorelin The most evidence-supported synergy in this stack comes from combining GHRH receptor activation (tesamorelin/CJC-1295 without DAC) with GHS-R1a activation (ipamorelin). GHS compounds and ghrelin receptor agonism stimulate GH release via signaling that is typically described as PLC/second-messenger (Ca²⁺/DAG)–linked, distinct from the cAMP-centric GHRH pathway [4]. Controlled mechanistic studies show that co-activation of the GHRH receptor and the GHS receptor can amplify intracellular signaling beyond either pathway alone. In a receptor-defined cell system expressing both receptors, activation of a GHS pathway (including ghrelin) potentiated the cAMP response to GHRH. The cAMP response approximately doubled compared with GHRH alone, suggesting receptor-level cross-talk that enhances somatotroph responsiveness [5]. This type of finding provides a strong rationale for pairing a GHRH analog with a selective GH secretagogue like ipamorelin when the goal is to model enhanced pulsatile GH dynamics rather than sustained GH elevation. Aside from muscle anabolism, CJC-1295 combined with ipamorelin may also activate chondrocytes and osteoblast differentiation, suggesting potential use for cartilage and bone regeneration [6]. Evidence for Combination Direct studies evaluating tesamorelin + CJC-1295 No DAC + ipamorelin as a three-agent combination are not well represented in the peer-reviewed literature. What does exist is: Evidence for GHRH + GHS/ghrelin synergy at the signaling level. Clinical and translational research on tesamorelin alone as a GHRH analog modulating GH/IGF-1 dynamics and downstream metabolic/immune markers in specific populations. CJC-1295–class GHRH analogs sustaining stimulation of GH/IGF-1. Broader endocrine literature describing ghrelin/GHS pharmacology and why GHS receptor agonism can amplify GH pulse amplitude. Given this, the most defensible conclusion is that the triple stack is mechanistically plausible, but not yet validated as a combined regimen in controlled clinical trials. Dosage At a conceptual level, allocating more total mass to the GHRH-analog component (e.g., tesamorelin 6 mg alongside lower-dose CJC-1295 No DAC and ipamorelin) can be interpreted as emphasizing primary drive through the traditional GHRH pathway, with ipamorelin positioned as a complementary amplifier via GHS-R1a cross-talk. Beyond that general framework, the optimal ratio is not established in public evidence and should be treated as an empirical design choice rather than a settled standard. References: 1 Adrian, S., Scherzinger, A., Sanyal, A., Lake, J. E., Falutz, J., Dubé, M. P., et al. (2019) The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J. Frailty Aging, SERDI 8, 154–159 2 Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P. and Frohman, L. A. (2006) Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J. Clin. Endocrinol. Metab. 91, 799–805 3 Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., et al. (1998) Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol., Oxford University Press (OUP) 139, 552–561 4 Akalu, Y., Molla, M. D., Dessie, G. and Ayelign, B. (2020) Physiological effect of ghrelin on body systems. Int. J. Endocrinol., John Wiley & Sons, Ltd 2020, 1385138 5 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582 6 Rahman, O. F., Lee, S. J. and Seeds, W. A. (2026) Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. J. Am. Acad. Orthop. Surg. Glob. Res. Rev., Ovid Technologies (Wolters Kluwer Health) 10, e25.00236

Character Snapshot In combination, tesamorelin and ipamorelin represent a dual-pathway approach to modulating endogenous GH pulsatility, leveraging established physiological interactions between GHRH and ghrelin signaling. While direct combination studies are limited, existing mechanistic and translational evidence supports further investigation of this pairing as a research model for coordinated GH axis regulation. Tesamorelin Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) composed of 44 amino acids, designed to stimulate endogenous, pulsatile growth hormone (GH) secretion from the anterior pituitary [1]. By binding to the GHRH receptor, tesamorelin activates cAMP-mediated signaling in somatotroph cells, promoting downstream increases in insulin-like growth factor-1 (IGF-1) while preserving normal feedback regulation [2]. Tesamorelin is a well-characterized tool for elucidating GHRH-driven regulation as both model organisms and clinical research have investigated for effects on [3]: GH axis modulation Lipid metabolism Visceral adipose tissue Ipamorelin Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively activates the ghrelin (GHS-R1a) receptor in the hypothalamus and pituitary [4]. Through this pathway, ipamorelin stimulates pulsatile growth hormone (GH) release without significantly increasing other pituitary hormones such as cortisol or prolactin. In research settings, ipamorelin has been investigated for its high signaling specificity and favorable endocrine selectivity, making it a complementary agent to GHRH analogs when studying coordinated regulation of endogenous GH secretion. Synergy The rationale for combining tesamorelin and ipamorelin is grounded in well-characterized physiological cross-talk between the GHRH and ghrelin/GHS signaling systems, which regulate the amplitude and timing of endogenous growth hormone (GH) pulses. Rather than acting redundantly, these peptides engage distinct but convergent control pathways within the somatotropic axis. Complementary mechanisms of action Tesamorelin is a GHRH analog that activates the GHRH receptor on pituitary somatotrophs, while Ipamorelin is a selective ghrelin (GHS-R1a) receptor agonist. GHS-R1a activation is typically associated with PLC-linked signaling, intracellular calcium mobilization, and enhanced somatotroph responsiveness [5]. Importantly, ghrelin/GHS signaling does not independently raise cAMP, but it can potentiate GHRH-driven cAMP responses when both receptors are engaged. An in vivo study examined whether ghrelin exhibited synergistic effects with growth hormone–releasing hormone (GHRH) on growth hormone (GH) secretion [6]. Normal adult male participants were given an intravenous administration of ghrelin at varying doses (0.08, 0.2, and 1.0 μg/kg), either alone or in combination with GHRH (1.0 μg/kg). Results showed that: At lower ghrelin doses (0.08 and 0.2 μg/kg), combined administration with GHRH resulted in a statistically significant synergistic increase in GH secretion (p < 0.05). At the higher, equivalent ghrelin dose (1.0 μg/kg), a similar trend toward synergy was observed, but with no statistical significance. No synergistic effects were observed for ACTH or prolactin, indicating pathway specificity for GH secretion. These findings demonstrate a selective and dose-dependent synergistic interaction between ghrelin and GHRH in stimulating GH release in humans. The absence of synergy for other pituitary hormones suggests that the interaction is specific to the somatotropic axis, rather than generalized pituitary activation. Direct clinical trials specifically evaluating tesamorelin combined with ipamorelin are limited. However, the broader literature provides several relevant lines of evidence: Cell-based and animal studies demonstrate synergistic GH release when GHRH and ghrelin or GHS compounds are co-administered, relative to either pathway alone [7,8]. Clinical and translational research on tesamorelin shows robust stimulation of pulsatile GH and downstream IGF-1 in populations with intact pituitary function [9,3]. Human pharmacology studies of GHS compounds, including ipamorelin-class peptides, illustrate selective GH release with minimal off-target pituitary hormone activation [6]. Taken together, this data supports the potential of tesamorelin–ipamorelin synergy via coordinated engagement of complementary regulatory pathways, even though formal combination trials remain sparse. Dosing From a research-design perspective, allocating a greater proportion of the total peptide mass to tesamorelin (7 mg) can be viewed as emphasizing primary drivers through the main GHRH pathway, which establishes pulse timing and baseline GH output. Ipamorelin (3 mg) can then function as a selective amplifier, enhancing somatotroph responsiveness through GHS-R1a–mediated cross-talk without broadly activating appetite or stress-related endocrine pathways. This lower ghrelin receptor agonist to GHRH ratio is in agreement with the literature in terms of producing synergistic GH secretion effects [6]. Beyond this high-level rationale, optimal dosing ratios are not established in the open literature and should be regarded as empirical parameters rather than evidence-based standards. References: 1 (2012) Bremelanotide. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD) 2 Halmos, G., Szabo, Z., Dobos, N., Juhasz, E. and Schally, A. V. (2025) Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev. Endocr. Metab. Disord., Springer Science and Business Media LLC 26, 343–352 3 Results from the 26-week Confirmatory, Phase 3 Trial of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Excess Abdominal Fat: A Multicenter, Double-blind, Placebo-controlled Study with 404 Randomized Patients https://www.natap.org/2008/IAS/IAS_56.htm 4 Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., et al. (2020) Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl. Androl. Urol., AME Publishing Company 9, S149–S159 5 Mear, Y., Enjalbert, A. and Thirion, S. (2013) GHS-R1a constitutive activity and its physiological relevance. Front. Neurosci., Frontiers Media SA 7, 87 6 Hataya, Y., Akamizu, T., Takaya, K., Kanamoto, N., Ariyasu, H., Saijo, M., et al. (2001) A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J. Clin. Endocrinol. Metab., The Endocrine Society 86, 4552 7 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582 8 Casanueva, F. F. and Dieguez, C. (1999) Growth hormone secretagogues: Physiological role and clinical utility. Trends Endocrinol. Metab., Elsevier BV 10, 30–38 9 Stanley, T. L., Chen, C. Y., Branch, K. L., Makimura, H. and Grinspoon, S. K. (2011) Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab., The Endocrine Society 96, 150–158